L
Lorenzo G. Mantovani
Researcher at University of Milan
Publications - 361
Citations - 38356
Lorenzo G. Mantovani is an academic researcher from University of Milan. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 51, co-authored 324 publications receiving 26740 citations. Previous affiliations of Lorenzo G. Mantovani include University of Naples Federico II & University of Milano-Bicocca.
Papers
More filters
Journal ArticleDOI
Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study
Paolo Cortesi,Claudio Mencacci,Ferrannini Luigi,Elvezio Pirfo,Patrizia Berto,Miriam C. J. M. Sturkenboom,Fabiana L Lopes,Maria Grazia Giustra,Lorenzo G. Mantovani,Luciana Scalone +9 more
TL;DR: The results suggest how tailoring the treatment strategy according to the complex and specific patient needs make it possible to achieve benefits and to allocate more efficiently resources.
Journal ArticleDOI
Economic evaluation in cardiology.
TL;DR: The economic approach from the perspective of cardiology is explained, designed to assist decision makers in allocating budgets in ways that will maximize value for money spent.
Journal ArticleDOI
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017:
Paolo Cortesi,Carla Fornari,Fabiana Madotto,Sara Conti,Mohsen Naghavi,Boris Bikbov,Paul S Briant,Valeria Caso,Giacomo Crotti,Catherine O. Johnson,Minh Nguyen,Luigi Palmieri,Norberto Perico,Francesco Profili,Giuseppe Remuzzi,Gregory A. Roth,Eugenio Traini,Fabio Voller,Simon Yadgir,Giampiero Mazzaglia,Lorenzo Monasta,Simona Giampaoli,Lorenzo G. Mantovani +22 more
TL;DR: A decline in cardiovascular mortality and disability-adjusted life years is shown, which reflects the success in reducing disability, premature death and early incidence of cardiovascular diseases, however, the burden of cardiovascular Diseases is still high.
Journal ArticleDOI
Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study.
Frederikus A. Klok,Stefano Barco,Alexander G.G. Turpie,Sylvia Haas,Reinhold Kreutz,Lorenzo G. Mantovani,Martin Gebel,Matthias Herpers,Joerg-Peter Bugge,Stavros V Kostantinides,Walter Ageno +10 more
TL;DR: The predictive value of VTE‐BLEED was similar in selected patients with unprovoked VTE or those treated with rivaroxaban or conventional anticoagulation, supporting the hypothesis that VTE-BLEED may be useful for making management decisions on the duration of antICOagulant therapy.
Journal ArticleDOI
XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis.
Walter Ageno,Lorenzo G. Mantovani,Sylvia Haas,Reinhold Kreutz,Verena Haupt,Jonas Schneider,Alexander G.G. Turpie +6 more
TL;DR: XALIA (XArelto for Long-term and Initial Anticoagulation in venous thromboembolism) is a multicentre, prospective, non-interventional, observational study investigating the effectiveness and safety of a single-drug approach with rivaroxaban compared with standard therapy in patients with DVT.